Osivax

Description

Osivax develops oligoDOM self-assembling nanoparticle vaccines that activate T-cell and B-cell immunity for broader protection against conserved viral antigens, applied to influenza, HPV and other infectious diseases.

Osivax is located in the Paris ecosystem.

Related

• CytuvaxCytuvax develops cancer immunotherapy and vaccines for viral and bacterial pathogens, using depot-attached cytokines as immune-stimulating…
• TILT BiotherapeuticsTILT Biotherapeutics develops oncolytic viral immunotherapies and engineered viral payloads to modify tumor microenvironments and enhance…
• BBelynticBelyntic develops T-Fender vaccines that use self-adjuvant, self-aggregating synthetic long peptides, combined with AI-based prediction, to…
• NexdotNexdot develops and manufactures quantum dot (Quantum Plates) materials, encapsulation and electro‑optic components for industrial…
• BraineverBrainever develops hEN1 and hOTX2 homeoprotein drug candidates intended to limit neurodegenerative disease progression by preventing…
• Bavarian NordicBavarian Nordic researches, develops, and manufactures life-saving vaccines, maintains product and pipeline materials, and operates process…
• EDX MedicalEDX Medical develops diagnostic tests and point-of-care devices that combine molecular biology and digital technologies to provide…
• Trained Therapeutix DiscoveryTrained Therapeutix Discovery develops nanobiologic therapeutics that regulate trained immunity for applications in cancer and organ…
• RobeautéRobeauté develops a brain microrobotic platform for neuro-interventions, using rice-sized microrobots and related infrastructure to better…